This document provides a summary of Alexander Polinkovsky's professional experience and education. It lists his positions from 2014 to present as a clinical and biomedical research consultant. It also outlines his previous roles as a research lab manager and researcher from 2011 to 2014 at the Louis Stokes V.A. Medical Center and from 2009 to 2011 at Case Western Reserve University. It notes that he has a Ph.D. in Biology and Virology from 1981 and has experience in areas like microbiome studies, DNA/RNA extraction, metabolomics, and proteomics.
CHI's Bioassays for Immuno-Oncology Symposium, Oct. 23, 2017 in Washington, DCJames Prudhomme
Biological assays demonstrating drug characteristics such as potency, mechanism-of-action, and stability, are one of the most critical components of an FDA biologic submission. However, with more complex mechanisms-of-action, immunotherapies add a layer of difficulty to bioassay selection and development. At Cambridge Healthtech Institute's Inaugural Bioassays for Immuno-Oncology symposium, experts in bioassays for immuno-oncology therapies will discuss selection, development, and standards for bioassays and immunoassays. Special attention will be given to understanding the mechanism-of-action for immunotherapies, whether they be antibody- or cell-based. Overall, this one-day immersive symposium will outline a product life cycle approach for developing and implementing biological assays from preclinical studies to clinical development. This symposium is part of the Immunogenicity & Bioassay Summit.
My first proposal, Everyone knows a person that have or had Cancer. We know that Cancer dosen't have a cure an yet the therapies for it, sometimes, do more harm to the person because the therapy do not choose what kind of cell is going to destroy. But if we can develop a new kind of treatment, a less agresive and more effective one, we will increase the survival chances and minimizes the secondary efects.
CHI's Bioassays for Immuno-Oncology Symposium, Oct. 23, 2017 in Washington, DCJames Prudhomme
Biological assays demonstrating drug characteristics such as potency, mechanism-of-action, and stability, are one of the most critical components of an FDA biologic submission. However, with more complex mechanisms-of-action, immunotherapies add a layer of difficulty to bioassay selection and development. At Cambridge Healthtech Institute's Inaugural Bioassays for Immuno-Oncology symposium, experts in bioassays for immuno-oncology therapies will discuss selection, development, and standards for bioassays and immunoassays. Special attention will be given to understanding the mechanism-of-action for immunotherapies, whether they be antibody- or cell-based. Overall, this one-day immersive symposium will outline a product life cycle approach for developing and implementing biological assays from preclinical studies to clinical development. This symposium is part of the Immunogenicity & Bioassay Summit.
My first proposal, Everyone knows a person that have or had Cancer. We know that Cancer dosen't have a cure an yet the therapies for it, sometimes, do more harm to the person because the therapy do not choose what kind of cell is going to destroy. But if we can develop a new kind of treatment, a less agresive and more effective one, we will increase the survival chances and minimizes the secondary efects.
El lunes 23 de octubre de 2017 celebramos una jornada en la Fundación Ramón Areces sobre Microbiota Intestinal: Implicaciones en la Salud y Enfermedad.
A normal cell can be transformed into a cancerous cell. Discuss the therapeutic strategies that are employed to target the cellular transformation process for cancer prevention and treatment.
Creating an app on Ribily Part 1
Create business apps essential for your business within hours. No IT skills needed.
Creating Discussions on Ribily to collaborate among your team members.
El lunes 23 de octubre de 2017 celebramos una jornada en la Fundación Ramón Areces sobre Microbiota Intestinal: Implicaciones en la Salud y Enfermedad.
A normal cell can be transformed into a cancerous cell. Discuss the therapeutic strategies that are employed to target the cellular transformation process for cancer prevention and treatment.
Creating an app on Ribily Part 1
Create business apps essential for your business within hours. No IT skills needed.
Creating Discussions on Ribily to collaborate among your team members.
The PO Fulfillment app is first of the apps I have planned to build for the ‘Build Fast Series’. It is an example of how quickly one can build an app on Ribily by leveraging the features of Ribily
Paperless On-Boarding on Ribily is the 3rd App built in the build fast series. It automates the process of getting stuff ready for the new Employee before his/her joining date.
Join us in Boston this coming Fall to attend Cambridge Healthtech Institute's (CHI) 2nd Annual FAST: Functional Analysis & Screening Technologies Congress on November 17-19, 2014 and meet with a community of 250+ biologists, screening managers, assay developers, engineers and pharmacologists dedicated to improving in vitro cell models and phenotypic screening to advance drug discovery and development at 6 conferences: Phenotypic Drug Discovery (Part I & II), Engineering Functional 3D Models, Screening and Functional Analysis of 3D Models, Organotypic Culture Models for Toxicology and Physiologically-Relevant Cellular Tumor Models for Drug Discovery. Delegates have the opportunity to share insights in interactive panel discussions and connect during networking breaks. View innovative technologies and scientific research revolutionizing early-stage drug discovery in the exhibit/poster hall.
1. ALEXANDER POLINKOVSKY, Ph.D.
23971 Fairmount Blvd., Beachwood, OH 44122
Home (216) 591-1524 Cell (216) 570-1681
e-mail: a.polinkovsky@gmail.com
PROFESSIONAL EXPERIENCE:
2014 – present Clinical and Biomedical Research Consultant.
2011 - 2014 Research Lab Manager/ Researcher
Research Service, Louis Stokes V.A. Medical Center, Cleveland, Ohio
2009 – 2011 Research Associate / Lab Manager
Research Assistant III / Lab Manager
Dept. of Neuroscience/Neurosurgery ,
Case Western Reserve University, Cleveland, Ohio
1998 - 2009 Research Associate / Lab Manager
Research Assistant III / Lab Manager
Dept. of Medicine, Hematology/Oncology
Case Western Reserve University. Cleveland, Ohio
1996-1998 Post-Doctoral Fellow
Department of Genetics, School of Medicine,
Case Western Reserve University. Cleveland, Ohio
1992- 1996 Consultant (Biotechnology and Plant Protection)
Maglionico’s Landscaping. Mantua, Ohio
1987-1991 Senior Research Scientist
Department of Virology. Moldavian Horticulture Research Center.
Kishinev, Moldova, USSR
1974-1987 Research Scientist
Department of Virology. Moldavian Horticulture Research Center.
Kishinev, Moldova, USSR
________________________________________________________
FORMAL EDUCATION
1981 Ph.D. ( Biology; Virology) National Horticultural Institute of Belorussia,
Minsk, Belorussia, USSR
1973 M.S. ( Biology; Phytopathology) Moldavian State University, Kishinev,
Moldova, USSR
2. Brief Details of Work Experience:
Self-employed as a consultant to both clinical medical laboratories (Lois Stokes Cleveland
Medical Center) and biomedical research laboratories (Case Western Reserve University, Case
Medical Center). For these consulting services I specialize in:
Microbiome studies using the latest molecular biology tools including Next Generation
Sequencing, emulsion-PCR, real time PCR, Droplet Digital PCR(ddPCR)
DNA, RNA extraction and purification from different type of tissue including single cell
lysates
Metabolomics for receiver operator curve analysis in silico modeling systems for advance
in vitro diagnostics
Proteomics using SELDI- and MALDI-TOF mass spectroscopy with several
bioinformatics databases
As Research lab manager and Researcher, my responsibilities included the training and
supervision of students and lab employees, as well as the coordination of the practical aspects of
all research projects in the lab. I maintained a lab supply inventory of over 850 items. I monitored
budget allocations for lab supplies and instrumentation. I also monitored advances in
instrumentation and brought information on new technological approaches to the attention of the
Principal Investigator such as: Next Generation Sequencing, emulsion-PCR. I conducted and
supervised studies in antibiotic resistance, including anaerobic and aerobic culture procedures. I
experimented with mouse models using established molecular tools (PCR, Real-time PCR,
Sequencing and Metabolomics).
Participated in studies on Brain tumors, in creating and developing primary glioma cells lines,
investigating the ability of genetically modified dendritic cells to elicit anti-tumor immunity.
Participated in the clinical trials. In earlier employment, I briefly studied the role of estrogen (and
other) receptors in the development of breast cancer. For a number of years I studied mismatch
repair mechanisms in DNA using Aza cytidine-induced damage. We focused on defining the
mechanisms of genotoxic damage induced by therapeutic agents and environmental mutagens. I
studied the impact of mutator defects in colon cancer cells with a view toward elucidating the
mechanisms of action of the mutagens. My work also included characterization of differentially
methylated regions using specific assays for methylated DNA, functional analysis of genes by
using knockdown/knockout approaches in cell lines and qRT- PCR analysis of gene expression.
Other duties in this position included:
• Performed experiments to investigate the ability of genetically modified dendritic cells to
promote anti-tumor immunity in a murine glioma model. Researched new and/or alternative
research methodologies and established working protocols in the lab.
• Responsible for ordering, inventory and supply tracking, purchasing, delegating responsibility
for routine shared lab duties.
• Day-to-day management of multidisciplinary NIH-funded research projects including design,
execution and troubleshooting of experiments;
• Tracking developments in the field and re-orienting research strategy and experimental
procedures;
3. • Training and supervision of technical and graduate personnel;
• Molecular Biology: cloning/ mutagenesis/ vector construction -bacterial and viral systems,
Western/Northern/Southern, qRT-PCR design including QC and validation (semi and
absolute quantitation), siRNA mediated gene knockdown;
• Epigenetic methods including restriction based identification of methylated regions in CpG
islands.
• In my post-doc Position, my projects included:
• Using PCR-based methods to perform genetic linkage analysis of connective tissue diseases;
• Detecting disease-associated mutations in the candidate genes by heteroduplex, single-
stranded conformation polymorphism (SSCP);
• DNA sequence analysis. In my capacity as Senior Research Scientist in the former Soviet
Union, my projects included:
• Diagnosing viral and mycoplasma diseases of plants;
• Creating and developed research methods for plant virology and epidemiology;
• Investigating the epidemiology of plant viruses and developed methods for the control of
vectors such as nematodes and insects.
REPRESENTATIVE PUBLICATIONS AND PRESENTATIONS:
R L Jump, A Polinkovsky, K Hurless, B Sitzlar, K Eckart, A Deshpande, M M Nerandzic, C J
Donskey (2014) Metabolomics Analysis Identifies Intestinal Microbiota-Derived Biomarkers of
Colonization Resistance in Clindamycin-Treated Mice. PLoS ONE 9(7): e101267.
doi:10.1371/journal.pone.0101267
Ma AH, Xia L, Littman S J, Swinler S, Lader G, Polinkovsky A, Olechnowicz J, Kasturi L,
Lutterbaugh J, Modrich P, Veigl M L, Markowitz S D, Sedwick W D. (2000) Somatic mutation of
hPMS2 as a possiblecause of sporadic human colon cancer with microsatellite instability. Oncogene
19:2249-2256.
Everman DB, Polinkovsky A, Francomano CA, Graham JM Jr, Goodman FR, Neri G, Morrison S,
Robin NH, and Warman ML. (1999) Additional CDMP1 mutations suggest that brachydactyly type C
is locus homogeneous and incompletely penetrant. Am J Hum Genet 65(suppl): A294,.
Kant, S.G., Polinkovsky, A., Mundlos, S., Zabel, B., Thomeer, R.T.W.M., Zonderland, H.M., van
Haeringen, A., and Warman, M.L. (1998) Acromesomelic dysplasia, Maroteaux type, maps to human
chromosome 9. Am. J. Hum. Genet. 63:155-162.
Bahabri, S.A., Suwairi, W.M., Laxer, R.M, Polinkovsky, A., Dalaan A.A. and Warman, M.L. (1998)
The camptodactyly-arthropathy-coxa vara-pericarditis syndrome. Arthritis & Rheumat. 41:730-735
Polinkovsky, A., Robin, N.H., Thomas, J.T., Irons, M., Lynn, A., Goodman F.R., Reardon, W., Kant,
S.G., Brunner, H.G., van der Burgt, I., Chitayat, D., Luyten, F.P., and Warman, M.L. (1997)
Mutations in CDMP1 cause autosomal dominant Brachydactyly type C. Nature Genet. 17:18-19.
4. Robin, N.H., Gunay-Aygun, M., Polinkovsky, A., Warman, M.L., and Morrison, S (1997) Clinical
and locus heterogeneity in Brachydactly type C. Am. J. Med. Genet. 68:369-377.
Polinkovsky A (1995): Geographical distribution of nematodes of the family
Longidoridae(Thorne,1935) Meyl,1960 in Moldova vineyards. Proceedings of APS Annual Meeting,
Pittsburg PA
Polinkovsky A (1993): The transmission of Plum Pox Virus in Moldova. Proceedings of 6th
International Congress of Plant Pathology, Montreal, Canada (1993)
Verderevskaya TD, Bivol TF, Marinescu VG, Polinkovsky AI et al.(1990): Technology of Production
of Virus Free Planting Material. Moscow, USSR 38p.
Polinkovsky AI, Andreev AV (1987):One-House Species of Plum Aphid as Vectors of Plum Pox
Virus. Proceedings of Academy of Science of Moldavian SSR. Biological and Chemical Sciences
Series, Kishinev, USSR 6:61-63
VerderevskayaTD, Vereshjagin BV, Andreev AV, Polinkovsky AI (1983): The Epidemiology of
Plum Pox Virus in Moldavia. Acta Horticulturae 130:317
Polinkovsky A (1980): Nematodes Vectors of Grapevine Viruses and Elaboration for Control with
Them in Moldavian SSR. Tag.-Ber.,Acad.Landwirtsh. Wiss, Berlin, Germany 184:303-312
Polinkovsky A (1979): Specific Composition and Geographic Distribution of Nematodes Logidoridae
(Nematoda Dorylaimoidae) in Moldavian vineyards. Proceedings of Academy of Science of
Moldavian SSR. Biological and Chemical Sciences Series. USSR 2:37-48
Sedwick, WD, Bao, C, Polinkovsky, A and Veigl , ML. DNA Methyltransferase I (DNMT1), An
Essential Enzyme for Maintenance of Gene Silenced Phenotypes in a Cell Line Isolated from A
Sporadic Colon Cancer. Presented at the 37
th
Annual Meeting of The Environmental Mutagen
Society, September 16-20, 2006, Vancouver, British Columbia, Canada. Environ. Molec Mutagen.,
47: 454.
Veigl , ML, Young, B, Polinkovsky, A, Strickfaden, S, and Sedwick, WD. Methylation Patterns
Underlying Epigenetic Regulation of Gene Expression in Mismatch Repair Defective Colon Cancer
Cell Lines. Presented at the 35
th
Annual Meeting of The Environmental Mutagen Society, October 2-
6, 2004, Pittsburgh, Pennsylvania.
Veigl, ML, Strickfaden S, Polinkovsky, A, Young, B, Leahy, P, and Sedwick, WD Genes
Epigenetically Co-Silenced with hMLH1 in Human Colon Cancer Cells. Presented at the ASM
Conference on DNA Repair and Mutagenesis: From Molecular Structure to Biological Consequences,
November 14-20, 2004; Southampton, Bermuda.
Veigl, M.L., Boothman, D.A., Strickfaden, S.M., Polinkovsky, A. and Sedwick, W.D. Toxicity of 5-
Fluoro-2-Deoxycytidine in hMLH1 Silenced-Colon Cancer Cells Occurs Coincident with Induced
Expression of hMLH1. (2002) Presented at the Environ. Mutagen Society Annual Meeting,
Anchorage, Alaska. Environ. & Molec. Mutagenesis, 39, Suppl 33: 209.
Ma, A-H, Xia, L., Swinler, S., Lader, G., Polinkovsky, A., Kasturi, L., Lutterbaugh, J., Modrich, P.,
Willson, J., Veigl, M.L., Markowitz, S.D.and Sedwick, W.D. Characterization of a Novel hPMS2
Deficient Human Colon Cancer Cell Line. Presented at the Amer. Assoc. Cancer Res. Annual
Meeting, Philadelphia, PA; Proc. Amer. Assoc. Cancer Res. (1999) 40: #915.